Aptose Biosciences Inc. (APTO) Analysts See $-0.13 EPS

March 7, 2018 - By Dolores Ford

 Aptose Biosciences Inc. (APTO) Analysts See $ 0.13 EPS

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.13 EPS on March, 27.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.11 EPS previously, Aptose Biosciences Inc.’s analysts see 18.18 % EPS growth. The stock increased 2.83% or $0.09 during the last trading session, reaching $3.27. About 1.64M shares traded or 200.71% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since March 7, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 13 by Roth Capital. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Wednesday, November 15 by H.C. Wainwright. H.C. Wainwright maintained Aptose Biosciences Inc. (NASDAQ:APTO) rating on Wednesday, August 9. H.C. Wainwright has “Hold” rating and $100 target. The rating was upgraded by Zacks to “Hold” on Friday, August 7. On Friday, November 20 the stock rating was downgraded by TH Capital to “Neutral”. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, November 11 report. The firm earned “Buy” rating on Wednesday, December 13 by H.C. Wainwright. The firm has “Buy” rating given on Thursday, September 7 by H.C. Wainwright. The firm has “Outperform” rating given on Wednesday, November 16 by RBC Capital Markets. H.C. Wainwright initiated the stock with “Hold” rating in Thursday, June 8 report.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $87.72 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More important recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Seekingalpha.com which released: “Aptose Biosciences’ (APTO) CEO William Rice on Q3 2017 Results – Earnings Call …” on November 15, 2017, also Globenewswire.com published article titled: “Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace …”, Seekingalpha.com published: “Aptose Looking Toward Human Studies” on September 20, 2017. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) was released by: Globenewswire.com and their article: “Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase …” with publication date: March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: